Xiuman Zhou

9PUBLICATIONS
24CO-AUTHORS
Tissue engineeringMicro- and nanosystemsMolecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Aug 07, 2026
T cell-nanodrug conjugates synchronize vascular normalization and immune activation for solid tumor therapy.

|Jan 22, 2026
An Engineered Nanovesicles-Based Lysosome-Targeting Protein Degradation Platform (NV-TACs) for Cancer Immunotherapy.

Youmei Xiao, Xiuman Zhou, Xiaoshuang Niu

|Feb 05, 2025
A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy.

Youmei Xiao, Zhuoying He, Wanqiong Li

|May 28, 2022
Identification of Immune Subtypes of Esophageal Adenocarcinoma to Predict Prognosis and Immunotherapy Response.

Chen Ling, Xiuman Zhou, Yanfeng Gao

|Oct 26, 2021
Identification of HLA-A2-Restricted Mutant Epitopes from Neoantigens of Esophageal Squamous Cell Carcinoma.

Zhiwei Wang, Ling Ran, Chunxia Chen

|Sep 28, 2021
Dual Blockade of Lactate/GPR81 and PD-1/PD-L1 Pathways Enhances the Anti-Tumor Effects of Metformin.

Shaomeng Chen, Xiuman Zhou, Xin Yang

Pageof 2

Frequent Collaborators

5 joint publications

Yanfeng Gao

4 joint publications

Xinghua Sui

2 joint publications

Yahong Wu

1 joint publications

Yan Lin